Therapy with macrolides in patients with cystic fibrosis

Pharmacotherapy

Volumn 22, Issue 2, 2002, Pages 227-239

  Gaylor, Allyson S ^a   Reilly, Joan C ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Farmington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

AUTOSOMAL RECESSIVE DISORDER; BIOFILM; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; INFLAMMATION; LUNG FUNCTION; MEDIATOR RELEASE; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT PLANNING;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; CLINICAL TRIALS; CYSTIC FIBROSIS; ERYTHROMYCIN; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; PSEUDOMONAS AERUGINOSA;

EID: 0036156534     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.3.227.33544     Document Type: Review

References (75)

1. Erythromycin and diffuse panbronchiolitis
2. Direct evidence for antipseudomonal activity of macrolides: Exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin
3. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm
4. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa
5. Effect of azithromycin on human serum sensitivity of Pseudomonas aeruginosa
6. Effects of azithromycin on the virulence of Pseudomonas aeruginosa
7. Antimicrobial agents: Tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents
8. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions
9. Clarithromycin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential
10. The pharmacokinetics of azithromycin in human serum and tissues
11. Erythromycin: A microbial and clinical perspective after 30 years of clinical use (first of two parts)
12. Pharmacokinetic data and drug monitoring. I. Antibiotics and antiarrhythmics
13. Macrolide drug interactions: An update
14. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut
15. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis
16. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias
17. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease
18. Ototoxicity with azithromycin
19. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus
20. Pharmacokinetics and pharmacodynamics of newer macrolides
21. Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease
22. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans
23. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin
24. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects
25. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses
26. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection
27. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection
28. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid
29. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma
30. Nonantibiotic effects of macrolide antibiotics of the oleandomycin-erythromycin group with special reference to their "steroid-sparing" effects
31. Macrolides, asthma, inflammation, and infection
32. The effect of troleandomycin on methylprednisolone elimination
33. Inhibition of theophylline clearance by troleandomycin
34. Nutrition and cystic fibrosis
35. The pathophysiology and treatment of cystic fibrosis
36. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis
37. Diffuse panbronchiolitis and cystic fibrosis: East meets west
38. Diffuse panbronchiolitis
39. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin
40. Long-term azithromycin may improve lung function in children with cystic fibrosis
41. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection
42. Therapies aimed at airway inflammation in cystic fibrosis
43. Erythromycin inhibits 132-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils
44. Inflammatory cytokines in cystic fibrosis lungs
45. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis
46. Significance of IL-1β and IL-1 receptor antagonist (IL-lRa) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)
47. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
48. Microbiology of cystic fibrosis
49. Immunopathogenesis of cystic fibrosis lung disease
50. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides
51. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro
52. Macrolide antibiotics in diffuse panbronchiolitis and in cystic fibrosis
53. Anti-inflammatory activity of macrolide antibiotics
54. Effect of clarithromycin on sputum production and its theological properties in chronic respiratory tract infections
55. Clindamycin, erythromycin, and roxithromycin inhibit the proinflammatory interactions of Pseudomonas aeruginosa pigments with human neutrophils in vitro
56. Intrapulmonary concentrations of antimicrobial agents
57. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study
58. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum
59. Azithromycin reduces TNF-α release from lipopolysaccharide stimulated mononuclear cells in cystic fibrosis
60. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro
61. Interleukin 1Β, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy
62. Induction by antitumoral drugs of proteins that functionally complement CFTR: A novel therapy for cystic fibrosis?
63. Azithromycin, the multidrug-resistant protein, and cystic fibrosis
64. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis
65. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro
66. Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa
67. Chloride transport may be restored by long-term azithromycin treatment in patients with cystic fibrosis
68. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation
69. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis
70. Prolonged beneficial effect of chronic azithromycin therapy on lung function in cystic fibrosis
71. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis